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Abstract
Background: MicroRNAs (miRNAs) are a novel class of endogenous, non-coding, single-stranded RNAs capable of
regulating gene expression by suppressing translation or degrading mRNAs. Single nucleotide polymorphisms (SNP)
can alter miRNA expression, resulting in diverse functional consequences. Previous studies have examined the
association of miRNA SNPs with breast cancer (BC) susceptibility. The contribution of miRNA gene variants to BC
susceptibility in South American women had been unexplored. Our study evaluated the association of the SNPs
rs895819 in pre-miR27a, rs11614913 in pre-miR-196a2, rs6505162 in pre-miR-423, rs4919510 in miR-608, and
rs2682818 in pre-mir-618 with familial BC and early-onset non-familial BC in non-carriers of BRCA1/2 mutations from
a South American population.
Results: We evaluated the association of five SNPs with BC risk in 440 cases and 807 controls. Our data do not
support an association of rs11614913:C > T and rs4919510:C > G with BC risk. The rs6505162:C > A was significantly
associated with increased risk of familial BC in persons with a strong family history of BC (OR = 1.7 [95 % CI 1.0–2.0]
p = 0.05). The rs2682818:C > A genotype C/A is associated with an increased BC risk in non-familial early-onset BC.
For the rs895819:A > G polymorphism, the genotype G/G is significantly associated with reduced BC risk in families
with a moderate history of BC (OR = 0.3 [95 % CI 0.1–0.8] p = 0.01).
Conclusions: The contribution of variant miRNA genes to BC in South American women had been unexplored. Our
findings support the following conclusions: a) rs6505162:C > A in pre-miR-423 increases risk of familial BC in families
with a strong history of BC; b) the C/A genotype at rs2682818:C > A (pre-miR-618) increases BC risk in non-familial
early-onset BC; and c) the G/G genotype at rs895819:A > G (miR-27a) reduces BC risk in families with a moderate
history of BC.
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Background
Breast cancer (BC) is the most common cancer among
women worldwide. In Chile, BC has the highest mortality
rate among cancers (15.8/100,000 women), and its inci-
dence has increased in all age groups analyzed [1]. Genetics
factors play an important role in BC development. Cur-
rently, there is consensus that mutations in genes BRCA 1
and BRCA 2 are responsible for an average 16 % of the risk
for familial BC [2]. It has been proposed that other suscep-
tibility alleles, called moderate or low penetrance, could be
responsible for a significant percentage of BC susceptibility.
To date, our group has studied the contribution of moder-
ate and low penetrance genes (PALB2 [3], BARD1 [4],
ATM [5], CHEK 2 [6], RAD51 [7], FGFR2 [8], MAP3K [8],
TOX 3 [9], 8q24 [9] and 2q35 [9]) to genetic susceptibility
for familial BC. Nevertheless, a large part of the genetic
component of familial cases remains unidentified [10]. Re-
search on known genes continues in order to further
understand BC development, with an emerging interest in
epigenetics and gene regulation. One of the most surprising
advances in understanding the mechanisms of gene regula-
tion has been the discovery of microRNA (miRNA) [11].
miRNAs are single-stranded RNAs of ~22 nucleotides that
can regulate gene expression by either degrading or block-
ing translation of target miRNA, mainly by binding to their
3’-UTR [12, 13]. MiRNAs are specific to different mRNAs,
and approximately 30 % of all human genes are regulated
by miRNA [14, 15]. The discovery of miRNAs has been
followed by findings highlighting their important and di-
verse roles in many molecular pathways and biological pro-
cesses, including development, apoptosis, differentiation,
and cell proliferation [16, 17], as well as their implication in
various human diseases including cancer. Growing evi-
dence indicates that miRNAs can work as oncogenes or
tumor suppressors, depending on which gene(s) they
modulate [18]. Atypical expression of various miRNAs has
been observed in the development and progression of nu-
merous human cancers [19–21]. Single nucleotide poly-
morphisms (SNPs) are the most common type of variation
in the human genome. SNPs present in the miRNA gene
regions can alter expression, lead to maturation to aberrant
miRNA, and affect target binding affinity and specificity
[22]. Many epidemiological studies have examined the asso-
ciation of miRNA SNPs with cancer susceptibility [19]. In
BC, several case–control studies and meta-analyses have
evaluated associations between miRNA gene polymor-
phisms and BC risk in European [23–28], Asian [29, 30],
Arab [31], and Jewish [32] populations. With the exception
of one study in a Brazilian population [33], the contribution
of variant miRNA genes to BC in South American women
had been unexplored. In this study, we selected specific
SNPs in five miR and evaluated the effects of these SNPs
on miR expression and biological function. Recent studies
have demonstrated that miR-27a exhibits oncogenic activity
by regulating specific transcription factors and the G2-M
checkpoint [34–36]. The rs895819:A >G is located at pos-
ition 40 relative to the first nucleotide of pre-miR-27a [37],
and it has been hypothesized that rs895819 could have an
effect on the secondary structure of pre-miR-27a, which
subsequently affects the processing and/or maturation of
miR-27a. Zhang et al. [38] showed that miR-27a expression
was significantly lower in BC samples with A/G or G/G ge-
notypes as compared to samples with A/A genotypes, indi-
cating that the A-to-G change decreases expression mature
miR-27a. The variant rs11614913, located in the mature
miR-196a-3p sequence, could lead to less efficient process-
ing of the miRNA precursor to its mature form and dimin-
ish its capacity to regulate target genes such as HOXB2,
HOXB3, HOXC3, HOXB5, GADD45G, INHBB, and TP63
[39]. Several studies have shown that miR-423 plays an im-
portant role in tumorigenesis [40–42]. In hepatocellular
carcinoma, miR-423 promotes cell growth and regulates
G(1)/S transition by targeting p21 Cip1/waf1 [40]. Zhao et
al. [43], demonstrated that the SNP rs6505162 in pre-miR-
423 affects mature miR expression, and miR-423 plays a
potentially oncogenic role in breast tumorigenesis. A few
polymorphisms are located in the mature microRNA se-
quence. Such polymorphisms could directly affect the bind-
ing of microRNAs to hundreds of target mRNAs. One of
these is rs4919510:C >G, located in mature miR-608. The
predicted targets of miR-608 include interleukin-1 alpha
(IL1A), growth hormone receptor (GHR), and TP53 [44].
These genes have been reported to be associated with BC
[45–47]. A study by Huang et al. [48] showed that the poly-
morphism rs4919510:C >G in the mature miR-608 se-
quence contributes to the risk of HER2+ BC. Deregulation
of miR-618 has previously been linked to a number of ma-
lignancies, including hepatocellular carcinoma [49], male
BC [50], and Barrett’s esophageal cancer [51]. Because SNP
rs2682818 is part of the miR-618 precursor’s stem-loop se-
quence, it can affect miR-618 levels. The SNP may alter the
secondary stem-loop structure, which in turn influences
how pre-miR-618 is processed into its mature form. [52].
Fu et al. [52] suggest that the presence of the variant A al-
lele may negatively impact the production of mature miR-
618 by interfering with the post-transcriptional miRNA
biogenic process. Considering the proceeding information,
in this study we evaluated the association of rs895819 in
pre-miR27a, rs11614913 in pre-miR-196a2, rs6505162 in
pre-miR-423, rs4919510 in miR-608, and rs2682818 in
pre-mir-618 with familial BC and early-onset non-familial
BC in non-carriers of BRCA1/2 mutations from a South
American population.
Methods
Families
A total of 440 BC cases (one case per family) belonging
to 440 high-risk BRCA1/2-negative Chilean families
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were selected from the files of the Servicio de Salud del
Area Metropolitana de Santiago, Corporación Nacional
del Cáncer (CONAC), and other private services in the
Metropolitan Area of Santiago. The majority of the cases
are from the Metropolitan Region, and all controls are
from the Metropolitan Region. All index cases were
tested for BRCA1 and BRCA2 mutations as previously
described [53]. Pedigrees were constructed on the basis
of an index case considered to have the highest probabil-
ity of being a deleterious mutation carrier. None of the
families met the strict criteria for other known syn-
dromes involving BC, such as Li-Fraumeni, ataxia-
telangiectasia, or Cowden disease.
Table 1 shows the specific characteristics of the families
selected according to the inclusion criteria. All families
participating in the study were of self-reported Chilean
ancestry dating from several generations, confirmed with
extensive interviews with several members of each family
from different generations. In the selected families; 16 %
(70/440) had cases of bilateral BC; 9 % (40/440) had cases
of both BC and ovarian cancer (OC); and 1.1 % (5/440)
had male BC. In the BC group, the mean age at diagnosis
was 42.1 years, and 75.2 % had age of onset <50 years.
This study was approved by the Institutional Review
Board of the School of Medicine of the University of
Chile. Informed consent was obtained from all of the
participants.
Control population
The sample of healthy Chilean controls (n = 807) was re-
cruited from CONAC files. DNA samples were taken
from unrelated individuals with no personal or family
history of cancer who consented to anonymous testing.
These individuals were interviewed and informed as to
the aims of the study. DNA samples were obtained in
accordance with all ethical and legal requirements. The
control sample was matched by age and socioeconomic
strata with respect to the cases.
Genotyping analysis
Genomic DNA was extracted from peripheral blood lym-
phocytes of 440 cases belonging to the selected high-risk
families and 807 controls. Samples were obtained accord-
ing to the method described by Chomczynski [54].
Genotyping of the SNPs rs11614913:C > T, rs6505162:C >
A, rs895819:A >G, rs2682818:C >A, and rs4919510:C >G
was performed using the commercially-available TaqMan
Genotyping Assay (Applied Biosystems, Foster City, CA)
(assay IDs C__31185852_10, C__11613678_10, C__305
6952_20, C__286717_10, and C__2826025_10, respectively).
The reaction was performed in a 10-uL final volume con-
taining 5 ng of genomic DNA, 1X TaqMan Genotyping
Master Mix, and 1X TaqMan SNP Genotyping Assay. The
polymerase chain reaction was carried out in a StepOne-
Plus Real-Time PCR System (Applied Biosystems, Foster
City, CA). The thermal cycles were initiated for 10 min at
95 °C, followed by 40 cycles each of 92 °C for 15 s and 60 °
C for 1 min. Each genotyping run contained DNA controls
confirmed by sequencing. The alleles were assigned using
the StepOne software V2.2 (Applied Biosystems, Foster
City, CA). As a quality control, we repeated the genotyping
on ~10 % of the samples, and all genotype scoring was per-
formed and checked separately by two reviewers unaware
of case–control status.
Statistical analysis
The Hardy-Weinberg equilibrium assumption was
assessed in the control sample using a goodness-of-fit
chi-square test (HW Chisq function included in the
“HardyWeinberg”.package v.1.4.1). Fisher’s exact test
was used to test the association between genotypes
and/or alleles for cases and controls. p < 0.05 was
used as the criterion of significance. Odds ratios (OR)
and 95 % confidence intervals (CI) were calculated to
estimate the strength of the associations in cases and
controls (odds ratio fisher function included in the
EpiTools package v.0.5 − 6).
Results
Selected characteristics of the 440 BRCA1/2-negative
cases are summarized in Table 1. For the analysis, the
whole case sample was subdivided into two groups:
cases with two or more family members with BC and/or
OC (n = 269) (subgroup A) and non-familial early-onset
BC (B ≤50 years) (n = 171) (subgroup B). The genotype
distributions and allele frequencies of the pre-miR-27a
rs895819:A > G, pre-miR-196a rs11614913:C > T, pre-
miR-423 rs6505162:C > A, miR-608 rs4919510:C > G,
and pre-miR-618 rs2682818:C > A polymorphisms in the
whole data set and in subgroups A and B with respect to
the controls are shown in Table 2. The observed geno-
type frequencies for four of the five polymorphisms were
in Hardy-Weinberg equilibrium in controls (p = 0.12 for
rs11614913:C > T, p = 0.7 for rs6505162:C > A, p = 0.3 for
rs4919510:C > G, and p = 0.8 for rs2682818:C > A, respect-
ively), while for rs895819:A >G the p-value was 0.02.
Table 1 Inclusion criteria for the families studied
Inclusion criteria Families: n (%)
Three or more family members with breast and/or
ovarian cancer
121 (27.5 %)
Two family members with breast and/or ovarian
cancer
148 (33.6 %)
Single affected individual with breast cancer≤ age 35 87 (19.8 %)
Single affected individual with breast cancer between
36 and 50 years of age
84 (19.1 %)
TOTAL 440 (100 %)
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Table 2 Genotype and allele frequencies of rs895819, rs11614913, rs6505162, rs4919510 and rs2682818 in BRCA1/2-negative breast
cancer cases and controls
All BC cases (n = 440) Families with ≥2 BC and/or
OC cases (n = 269)
Families with a single case,
diagnosed at ≤50 years of
age (n = 171)
Genotype or
allele
Controls (%)
(n = 807)
BC cases (%) p-valuea OR [95 % CI] BC cases (%) p-valuea OR [95 % CI] BC cases (%) p-valuea OR [95 % CI]
rs895819 (Pre-miR 27a)
A/A 432 (53 %) 245 (56 %) - 1.0 (ref) 146 (54 %) - 1.0 (ref) 99 (58 %) - 1.0 (ref)
A/G 298 (37 %) 166 (38 %) 0.9 0.9 [0.7–1.2] 105 (39 %) 0.8 1.0 [0.7–1.3] 61 (36 %) 0.5 0.8 [0.6–1.2]
G/G 77 (10 %) 29 (6 %) 0.08 0.6 [0.4–1.0] 18 (7 %) 0.1 0.6 [0.4–1.1] 11 (6 %) 0.1 0.6 [0.3–1.2]
A/G + G/G 375 (47 %) 195 (44 %) 0.4 0.9 [0.7–1.1] 123 (46 %) 0.8 0.9 [0.7–1.2] 72 (42 %) 0.3 0.8 [0.6–1.1]
Allele A 1162 (0.72) 656 (0.75) - 1.0 (ref) 397 (0.74) - 1.0 (ref) 259 (0.76) - 1.0 (ref)
Allele G 452 (0.28) 224 (0.25) 0.1 0.8 [0.7–1.0] 141 (0.26) 0.4 0.9 [0.7–1.1] 83 (0.24) 0.1 0.8 [0.6–1.0]
rs11614913 (Pre-miR 196a2)
C/C 342 (42 %) 192 (44 %) - 1.0 (ref) 113 (42 %) - 1.0 (ref) 79 (46 %) - 1.0 (ref)
C/T 351 (44 %) 191 (43 %) 0.8 0.9 [0.7–1.2] 127 (47 %) 0.5 1.0 [0.8–1.4] 64 (38 %) 0.2 0.7 [0.5–1.1]
T/T 114 (14 %) 57 (13 %) 0.5 0.8 [0.6–1.2] 29 (11 %) 0.3 0.7 [0.4–1.2] 28 (16 %) 0.8 1.0 [0.6–1.7]
C/T + T/T 465 (58 %) 248 (56 %) 0.6 0.9 [0.7–1.2] 156 (58 %) 0.9 1.0 [0.7–1.3] 92 (54 %) 0.3 0.8 [0.6–1.1]
Allele C 1035 (0.64) 575 (0.65) - 1.0 (ref) 353 (0.66) - 1.0 (ref) 234 (0.66) - 1.0 (ref)
Allele T 579 (0.36) 305 (0.35) 0.5 0.9 [0.8–1.1] 185 (0.34) 0.5 0.9 [0.7–1.1] 120 (0.34) 0.5 0.9 [0.7–1.1]
rs6505162 (Pre-miR 423)
C/C 284 (35 %) 125 (28 %) - 1.0 (ref) 74 (28 %) - 1.0 (ref) 51 (30 %) - 1.0 (ref)
C/A 385 (48 %) 229 (52 %) 0.02 1.3 [1.0–1.8] 141 (52 %) 0.03 1.4 [1.0–1.9] 88 (51 %) 0.2 1.3 [0.9–1.9]
A/A 138 (17 %) 86 (20 %) 0.05 1.4 [1.0–1.9] 54 (20 %) 0.05 1.5 [1.0–2.3] 32 (19 %) 0.3 1.3 [0.8–2.1]
C/A + A/A 523 (65 %) 315 (72 %) 0.01 1.4 [1.2–1.8] 195 (72 %) 0.02 1.4 [1.0–1.9] 120 (70 %) 0.1 1.3 [0.9–1.8]
Allele C 953 (0.59) 479 (0.54) - 1.0 (ref) 289 (0.54) - 1.0 (ref) 190 (0.56) - 1.0 (ref)
Allele A 661 (0.41) 401 (0.46) 0.02 1.2 [1.0–1.4] 249 (0.46) 0.03 1.2 [1.0–1.5] 152 (0.44) 0.2 1.1 [0.9–1.4]
All BC cases (n = 440) Families with ≥2 BC and/or
OC cases (n = 269)
Families with a single case,
diagnosed at ≤50 years of
age (n = 171)
Genotype or
allele
Controls (%)
(n = 807)
BC cases (%) p-valuea OR [95 % CI] BC cases (%) p-valuea OR [95 % CI] BC cases (%) p-valuea OR [95 % CI]
rs4919510 (miR 608)
C/C 431 (53.4 %) 226 (51 %) - 1.0 (ref) 141 (52 %) - 1.0 (ref) 85 (50 %) - 1.0 (ref)
C/G 310 (38.4 %) 174 (40 %) 0.6 1.0 [0.8–1.4] 104 (39 %) 0.8 1.0 [0.7–1.3] 70 (41 %) 0.4 1.1 [0.8–1.6]
G/G 66 (8.2 %) 40 (9 %) 0.5 1.1 [0.7–1.7] 24 (9 %) 0.6 1.1 [0.6–1.8] 16 (9 %) 0.5 1.2 [0.6–2.2]
G/G + C/G 376 (46.6 %) 214 (49 %) 0.5 1.0 [0.8–1.3] 128 (48 %) 0.7 1.0 [0.7–1.3] 86 (50 %) 0.4 1.1 [0.8–1.6]
Allele C 1172 (0.73) 626 (0.71) - 1.0 (ref) 386 (0.72) - 1.0 (ref) 240 (0.70) - 1.0 (ref)
Allele G 442 (0.27) 254 (0.29) 0.4 1.0 [0.9–1.3] 152 (0.28) 0.7 1.0 [0.8–1.3] 102 (0.30) 0.3 1.1 [0.8–1.4]
rs2682818 (Pre-miR 618)
C/C 699 (86.6 %) 359 (81.6 %) - 1.0 (ref) 221 (82 %) - 1.0 (ref) 139 (81 %) - 1.0 (ref)
C/A 102 (12.6 %) 78 (17.7 %) 0.01 1.4 [1.0–2.0] 45 (17 %) 0.1 1.4 [0.9–2.1] 32 (19 %) 0.04 1.6 [1.0–2.4]
A/A 6 (0.7 %) 3 (0.7 %) 1.0 0.9 [0.2–3.9] 3 (1 %) 0.4 1.5 [0.3–6.3] 0 (0 %) 0.5 0.3 [0.02–6.8]
C/A + A/A 108 (13.3 %) 81 (18.4 %) 0.02 1.4 [1.0–2.0] 48 (18 %) 0.08 1.4 [0.8–2.0] 32 (19 %) 0.07 1.4 [0.9–2.3]
Allele C 1500 (0.93) 796 (0.90) - 1.0 (ref) 487 (0.91) - 1.0 (ref) 310 (0.91) - 1.0 (ref)
Allele A 114 (0.07) 84 (0.10) 0.03 1.3 [1.0–1.8] 51 (0.09) 0.08 1.3 [0.9–1.9] 32 (0.09) 0.1 1.3 [0.9–2.0]
BC breast cancer, OC ovarian cancer, OR odds ratio, CI confidence interval
aFisher’s exact test
Bold values are statistically significant (p < 0.05)
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In the single locus analyses, no significant differences
were observed in the genotype and allele distributions
for rs11614913:C > T or rs4919510:C > G, either in the
whole data set or in subgroups A or B (p > 0.05). With
respect to rs6505162:C > A, the genotype and allele
distribution was significantly different in the whole sam-
ple of BRCA1/2-negative cases and in subgroup A, with
respect to the controls (p ≤ 0.05). The minor allele fre-
quency (MAF) (allele A) was higher in subgroup A cases
than in controls (0.46 and 0.41, respectively, p = 0.03).
Furthermore, in subgroup A, allele A carriers (C/A + A/
A) had a significantly increased BC risk (OR = 1.4 [95 %
CI 1.0 − 1.9] p = 0.02) (Table 2). We also analyzed the re-
lationship between rs6505162 and BC risk within cases
with a history familial BC according to number of BC
cases in the family (Table 3). No association between
rs6505162 and BC risk was found in cases belonging to
families with two BC and/or OC cases. However, BC risk
was significantly higher in cases with three or more fam-
ily members affected by BC and/or OC. In these fam-
ilies, the allele A frequency was 0.48 in BC cases versus
0.41 in controls (OR = 1.3 [95 % CI 1.0 − 1.7] p = 0.04),
and homozygous A/A were had a significantly increased
BC risk (OR = 1.7 [95 % CI 1.0 − 2.0] p = 0.05). No asso-
ciation was found between rs6505162 and non-familial
early-onset BC (≤50 years) (Table 2). For rs2682818,
located in pre-mir-618, in the whole sample, the MAF
(allele A) was higher in cases (0.1) than controls (0.07),
and the difference was statistically significant (OR = 1.3
[95 % CI 1.0 − 1.8] p = 0.03). This result indicates that
allele A is associated with increased BC risk. We also
observed increased BC risk for allele A carriers (C/A +
A/A) in the whole sample (OR = 1.4 [95 % CI 1.0 − 2.0]
p = 0.02) (Table 2). When we analyzed the effect of allele
A by number of BC cases per family, no association be-
tween rs2682818 and BC risk was found. Nevertheless,
BC risk increased 1.6-fold in the heterozygous group
(OR = 1.6 [95 % CI 1.0 − 2.4] p = 0.04) with non-familial
early-onset BC (≤50 years) (Table 3).
The results for rs895819 showed that the homozygous
genotype G/G was marginally associated with a protective
effect in the whole sample (OR = 0.6 [CI 0.4 − 1.0] p =
0.08). Nevertheless, in the families with 2 BC and/or OC
cases, we observed decreased BC risk associated with
Table 3 Genotype and allele frequencies of rs895819, rs11614913, rs6505162, rs4919510, and rs2682818 by number of BC cases per
family, in BRCA1/2-negative breast cancer cases and controls
Families with 2 BC and/or OC cases (n = 148) Families with ≥3 BC and/or OC cases (n = 121)
Genotype or allele Controls (%) (n = 807) BC cases (%) p-valuea OR [95 % CI] BC cases (%) p-valuea OR [95 % CI]
rs895819 (Pre-miR 27a)
A/A 432 (53 %) 83 (56 %) - 1.0 (Ref) 63 (52 %) - 1.0 (Ref)
A/G 298 (37 %) 60 (41 %) 0.8 1.0 [0.7–1.5] 45 (37 %) 0.9 1.0 [0.6–1.5]
G/G 77 (10 %) 5 (3 %) 0.01 0.3 [0.1–0.8] 13 (11 %) 0.6 1.1 [0.6–2.2]
A/G + G/G 375 (47 %) 65 (44 %) 0.5 0.9 [0.6–1.2] 58 (48 %) 0.7 1.0 [0.7–1.5]
Allele A 1162 (0.72) 226 (0.76) - 1.0 (Ref) 171 (0.71) - 1.0 (Ref)
Allele G 452 (0.28) 70 (0.24) 0.1 0.7 [0.5–1.0] 71 (0.29) 0.7 1.0 [0.7–1.4]
rs6505162 (Pre-miR 423)
C/C 284 (35 %) 41 (28 %) - 1.0 (Ref) 33 (27 %) - 1.0 (Ref)
C/A 385 (48 %) 81 (55 %) 0.07 1.4 [0.9–2.2] 60 (50 %) 0.2 1.3 [0.8–2.1]
A/A 138 (17 %) 26 (17 %) 0.3 1.3 [0.8–2.2] 28 (23 %) 0.05 1.7 [1.0–2.0]
C/A + A/A 523 (65 %) 107 (72 %) 0.08 1.4 [1.0–2.1] 88 (73 %) 0.09 1.4 [0.9–2.2]
Allele C 953 (0.59) 163 (055) - 1.0 (Ref) 126 (0.52) - 1.0 (Ref)
Allele A 661 (0.41) 133 (0.45) 0.2 1.2 [0.9–1.5] 116 (0.48) 0.04 1.3 [1.0–1.7]
rs2682818 (Pre-miR 618)
C/C 699 (86.6 %) 120 (81 %) - 1.0 (Ref) 101 (83.5 %) - 1.0 (Ref)
C/A 102 (12.6 %) 26 (18 %) 0.1 1.3 [0.9–2.3] 19 (15.7 %) 0.3 1.3 [0.7–2.2]
A/A 6 (0.7 %) 2 (1 %) 0.3 1.9 [0.3–9.7] 1 (0.8 %) 1.0 1.1 [0.1–9.6]
C/A + A/A 108 (13.3 %) 28 (19 %) 0.09 1.5 [1.0–2.5] 20 (16.5 %) 0.3 1.2 [0.7–2.1]
Allele C 1500 (0.93) 266 (0.90) - 1.0 (Ref) 221 (0.91) - 1.0 (Ref)
Allele A 114 (0.07) 30 (0.10) 0.07 1.4 [0.9–2.2] 21 (0.09) 0.3 1.2 [0.7–2.0]
BC breast cancer, OC ovarian cancer, OR odds ratio, CI confidence interval
aFisher’s exact test
Bold values are statistically significant (p < 0.05)
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homozygous minor allele genotype (G/G genotype, OR =
0.3 [95 % CI 0.1 − 0.8] p = 0.01). This result indicates that
the G/G genotype is associated with a protective effect in
families with a moderate history of BC.
Discussion
Mutations in BRCA1 and BRCA2 are associated with
susceptibility to breast and ovarian cancer. At present,
however, those mutations account for only a portion of
familial cases, and consequently there is an intensive
search for additional targets.
MiRNAs are a class of endogenous, non-coding,
single-strand RNAs involved in many molecular path-
ways and biological processes including apoptosis, dif-
ferentiation, proliferation, and immune response [55].
SNPs are the most common form of variation present
in the human genome. SNPs in miRNA gene regions
can affect miRNA function by modulating the tran-
scription of the primary transcript, pri-miRNA and
pre-miRNA processing, maturation, or miRNA-mRNA
interaction, which could contribute to cancer suscepti-
bility [56]. Recently, many epidemiological studies
have examined the association of miRNA SNPs with
BC susceptibility, but the results remain inconclusive.
Genetic variability is ethnicity-specific, and to date the
most miRNA SNP studies have been performed in
cases from European, Asian, Arab, and Jewish
populations, mainly with sporadic BC. With the ex-
ception of one study in a Brazilian population, the role
of miRNA variation in BC susceptibility has not been
analyzed in a Latin-American population. In the
present study, we evaluated the impact of miRNA
SNPs on familial and non-familial early-onset BC cases
negative for point mutations in BRCA1/2, from a Chilean
population. To this end, we studied the association of BC
risk with rs895819 in pre-miR27a, rs11614913 in pre-miR-
196a2, rs6505162 in pre-miR-423, rs4919510 in miR-608,
and rs2682818 in pre-mir-618 in a case–control study.
Table 4 shows the results of association studies between
SNPs: rs895819 (mir-27a), rs11614913 (miR196a2),
rs6505162 (miR-423), rs4919510 (miR-608), rs2682818
(miR-618) and BC risk in others populations.
Our data do not support an association of rs11614913:C >
T and rs4919510:C >G with breast cancer risk. With re-
spect to rs11614913, several case–control studies have been
conducted to investigate the association between this SNP
with BC susceptibility, but the results have been contradict-
ory. Specifically, case–control studies have shown that
rs11614913 SNP is associated with increased BC risk in
Han Chinese [29] and Saudi Arabian [57] populations. In
contrast, results from studies performed in the United
States [58] and China [59] showed that rs11614913 was as-
sociated with decreased BC susceptibility. Other studies in
Italian, German, and Australian populations reported that
Table 4 Results of association studies of SNPs rs895819, rs11614913, rs6505162, rs4919510 and rs2682818 with BC risk in different
populations
dbSNP Reference
n. MiRNA (variation) Phenotype Author(s) Country Ethnicity N (cases) N (controls)
1 miR-27a rs895819 Reduced familial BC Yang R., et al. (2010) [20] Germy Caucasian 1217 1422
Kontorovich T., et al. (2010) [26] Israel Jewish 279 212
Catucci I., et al. (2012) [18] Italy Caucasian 1025 1593
Zhang M.et al. (2012) [24] China Asian 252 248
Wang B., et al. (2014) [16] meta-analysis
2 miR-196a2 rs11614913 Increased BC risk Hu Z., et al. (2009) [23] China Asian 1009 1093
Hoffman AE., et al. (2009) [51] USA Caucasian 439 478
Catucci I., et al. (2010) [17] Italy Caucasian 760 1243
Catucci I., et al. (2010) [17] Germany Caucasian 1134 1517
Jedlinski DT., et al. (2011) [53] Australia Caucasian 187 171
Alshatwi A., et al. (2012) [25] Saudi Arabia Arabian 100 100
Zhang M.et al. (2012) [24] China Asian 252 248
Linhares JJ., et al. (2012) [27] Brazil Brazilian 388 388
Srivastava K., et al. (2012) [50] meta-analysis 3449 4140
3 miR-423 rs6505162 Increased BC risk Kontorovich T., et al. (2010) [26] Israel Jewish 279 212
Smith R., et al. (2012) [57] Australia Caucasian 179 174
4 miR-608 rs4919510 Increased HERB2 + BC risk Huang A-J.et al. (2012) [42] China Asian 252 248
5 miR-618 rs2682818 Increased BC risk Zhang M.et al. (2012) [24] China Asian 252 248
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the common SNP rs11614913 was not associated with in-
creased BC risk [23, 60]. In Brazilian women with BC, the
C/C genotype was associated with decreased BC risk, and
the presence of the T allele was significantly associated with
increased BC risk [33]. These discrepancies might be ex-
plained by different genetic backgrounds. The contempor-
ary Chilean population stems from the admixture of
Amerindian peoples with the Spanish settlers in the six-
teenth and seventeenth centuries. Later (nineteenth cen-
tury) migrations of Germans, Italians, Arabs, and Croatians
have had only a minor impact on the overall population
(not more than 4 % of the total population) and are re-
stricted to the specific locations of the country where they
settled [61]. The relationship between ethnicity, Amerindian
admixture, genetic markers, and socioeconomic strata has
been extensively studied in Chile [62, 63]. Thus, it is prob-
able that in the mixed Chilean population, rs11614913 is
not a significant contributor to BC, similar to the re-
sults described for Caucasian populations. Another
SNP found to have no association with BC risk in
our study, rs4919510:C > G, is located in mature miR-
608. This is important because few polymorphisms
are located in the mature microRNA sequence. More-
over, predicted targets of miR-608 include interleukin-
1 alpha (IL-1A), growth hormone receptor (GHR),
and TP53 [44], all of which have reported associations
with BC. The only case–control study, performed by
Huang et al. [48] in Han Chinese women, reported
that variant genotypes (C/G + G/G) were specifically
associated with increased risk for the HER2-positive
subtype in the recessive model, but not for other sub-
types. In the Chilean population, we observed no as-
sociation between this SNP and BC in the whole data
set, the familial BC group (subgroup A), or the non-
familial early-onset BC group (subgroup B). Neverthe-
less, our results are not comparable with those obtained in
the Han Chinese women as our study did not consider
pathologic features of the BC. Further studies in different
ethnic groups are needed before concluding whether
rs4919510:C > G alters BC susceptibility.
Several studies have evaluated the association between
the SNP rs6505162 in pre-miR-423 and cancer risk in di-
verse populations and in different cancers, with contra-
dictory outcomes. Nevertheless, there have been scarce
association studies on this SNP and BC or OC risk.
Kontorovich et al. [32] indicated that rs6505162 was asso-
ciated with a significantly increased risk of ovarian cancer;
on the contrary, Smith [64] showed that it conferred a re-
duced risk of BC. A meta-analysis published by Chen et
al. [22] reported no associations between the rs6505162
SNP and BC risk in any genetic model. However, this
meta-analysis included only two association studies in-
volving rs6505162 SNP, which is an important limitation
to interpreting the results. In our study, we found that the
SNP rs6505162:C > A was significantly associated with in-
creased risk of familial BC in the group with a strong fam-
ily history of BC. In these families, the homozygous
genotype A/A was associated with increased BC risk (OR
= 1.7 [95 % CI 1.0 − 2.0] p = 0.05). Our results are in ac-
cordance with the recent results obtained by Zhao et al.
[43], who demonstrated that the SNP rs6505162 in pre-
miR-423 affects mature miRNA expression and that miR-
423 plays a potentially oncogenic role in breast cancer
tumorigenesis.
miR-618 deregulation has been related to a number of
malignancies, such as hepatocellular carcinoma, [49], male
breast cancer [50], and Barrett’s esophageal cancer [51],
suggesting a potential rol of this miRNA as a possible can-
cer biomarker. Because SNP rs2682818 is part of the miR-
618 precursor’s stem-loop sequence, it can affect miR-618
levels. The SNP may alter the secondary stem-loop struc-
ture, which in turn influences how pre-miR-618 is proc-
essed into its mature form [52]. Recently, Fu et al. [52]
reported that rs2682818:C >A may play a role in suscepti-
bility to follicular lymphoma (OR= 1.65 [95 % CI 1.05–
2.50]).; an in vitro analysis indicated that the variant A allele
of rs2682818 lowered mature miR-618 levels. This reduc-
tion could trigger a deregulation of miR-618–controlled
pathways associated with follicular lymphoma. With respect
to BC, the only case–control study published to date re-
ported no association between rs2682818 and BC risk in a
Chinese population [30]. Our results showed that the
rs2682818 C/A genotype is associated with an increased
BC risk both in the whole sample and in the group with
non-familial early-onset BC. Our results are the first to
contribute to identification of rs6505162 in pre-miR-423
and rs2682818 in pre-miR-618 as polymorphisms associ-
ated with increased BC risk in a South American
population.
Six studies, including three meta-analyses, have exam-
ined the association between the rs895819 polymorphism
in miR-27a and BC risk. The studies were conducted in
German cases with familial BC, in Italian cases with famil-
ial BC, and in Chinese cases with sporadic BC. In the
German familial BC cases, the rare (G) allele was shown to
have a protective effect limited to cases with age at diagno-
sis <50 years (OR = 0.83 [95 % CI 0.70 − 0.98] p = 0.0314)
and bilateral BC (OR = 0.70 [95 % CI 0.52 − 0.95] p =
0.0238). The results obtained by Catucci et al. [24] in Ital-
ian familial BC failed to support the association of
rs895819 with BC risk. In a Chinese population, Zhang et
al. [38] showed that in sporadic BC, only younger
(<48 years old) allele G (A/G +G/G) carriers showed a sig-
nificantly reduced BC risk (OR = 0.535 [95 % CI 0.321 −
0.891] p = 0.016). With respect to the meta-analyses, the
first, which included 4 studies, concluded that subjects car-
rying the rs895819 G allele showed reduced BC risk [65].
The meta-analysis published by Bai et al. [66] found a
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significant association between rs895819 allele G and re-
duced BC risk in Caucasians, but not in Asians. A protect-
ive effect of rs895819 allele G was seen in the younger BC
cases and in the subgroup of unilateral BC cases. In
addition, the meta-analysis published by Chen et al. [22]
reported that the miR-27a rs895819 G allele might be a
protective factor for BC among Caucasians. Our results in
a Chilean mixed population showed that the MAF (allele
G) in the controls was low (0.28), similar to the East Asian
population [67]. In the whole sample, we observed a mar-
ginally protective effect of the genotype G/G, which was
likely attributable to SNP frequency and sample sizes.
Nevertheless, in the subgroup A, which included families
with a moderate BC history, the G/G genotype is signifi-
cantly associated with reduced BC risk. These results are
consistent with the meta-analysis which reported reduced
BC risk in Caucasians, as the Chilean population is 60 %
Caucasian [68].
Conclusions
The contribution of miRNA-gene variants to BC suscep-
tibility in South-American women had been unexplored,
with the exception of one study in a Brazilian popula-
tion. Our findings support the following conclusions: a)
rs6505162:C > A in pre-miR-423 increases risk of familial
BC in families with a strong history of BC; b) the C/A
genotype at rs2682818:C > A (pre-miR-618) increases BC
risk in non-familial early-onset BC; and c) the G/G
genotype at rs895819:A > G (miR-27a) reduces BC risk
in families with a moderate history of BC.
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